#48 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Veterans currently using cannabis or pursuing psychedelic therapy outside the VA system risk losing continuity of care, benefits eligibility concerns, and lack of clinical supervision that a formal federal program would provide.
Veterans organizations are pressing Congress to broaden access to both cannabis and psychedelic-assisted therapies through the VA system as a response to the persistently high suicide rate among veterans. The push reflects growing clinical evidence that current pharmacological and psychological treatment options are failing a significant portion of this population, particularly those with treatment-resistant PTSD and co-occurring substance use disorders. Expanding federally sanctioned access would allow VA clinicians to incorporate these therapies into structured treatment protocols rather than leaving veterans to seek care outside the system or through unregulated channels.
“When the suicide rate among a specific patient population remains catastrophically elevated for decades, continuing to restrict the most promising emerging therapies is not caution, it is negligence dressed up as policy.”
The advocacy by veteran organizations for expanded access to psychedelics and cannabis represents an important clinical acknowledgment that conventional treatment approaches have significant limitations for treatment-resistant PTSD and related conditions. ๏ธ Current evidence suggests both cannabinoids and psychedelic-assisted therapies may address distinct neurobiological pathways involved in trauma processing and emotional regulation, though each requires careful patient selection and monitoring. Integration of these modalities within the VA system would require substantial infrastructure development, provider training, and standardized protocols to ensure safe and effective implementation. The suicide prevention imperative among veterans justifies rigorous exploration of these options through properly designed clinical trials and compassionate access frameworks. Any expansion must be paired with robust safety monitoring and clear guidelines regarding patient populations most likely to benefit.
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it: